---
title: "SBC MEDICAL GROUP HOLDINGS INCRPRTD C/WTS 17/09/2029 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 43.35 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265918811.md"
datetime: "2025-11-14T12:04:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265918811.md)
  - [en](https://longbridge.com/en/news/265918811.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265918811.md)
generator: "portal-rs"
---

# SBC MEDICAL GROUP HOLDINGS INCRPRTD C/WTS 17/09/2029 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 43.35 M

Revenue: As of FY2025 Q3, the actual value is USD 43.35 M.

EPS: As of FY2025 Q3, the actual value is USD 0.12.

EBIT: As of FY2025 Q3, the actual value is USD 15.81 M.

### Segment Revenue

-   **Franchising Revenue**: $9,929,387 for the three months ended September 30, 2025, a decrease of 36.71% from $15,688,528 for the same period in 2024.
-   **Procurement Revenue**: $13,406,905 for the three months ended September 30, 2025, a decrease of 23.70% from $17,571,299 for the same period in 2024.
-   **Management Services Revenue**: $9,462,183 for the three months ended September 30, 2025, a decrease of 21.87% from $12,110,764 for the same period in 2024.
-   **Rental Services Revenue**: $6,219,645 for the three months ended September 30, 2025, an increase of 50.79% from $4,124,774 for the same period in 2024.
-   **Other Revenues**: $4,335,115 for the three months ended September 30, 2025, an increase of 20.77% from $3,589,518 for the same period in 2024.

### Operational Metrics

-   **Net Income**: $12,833,326 for the three months ended September 30, 2025, an increase of 352.76% from $2,834,467 for the same period in 2024.
-   **Gross Profit**: $30,611,487 for the three months ended September 30, 2025, a decrease of 29.20% from $43,239,090 for the same period in 2024.
-   **Operating Expenses**: $14,730,247 for the three months ended September 30, 2025, a decrease of 49.90% from $29,404,487 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $27,295,426 for the nine months ended September 30, 2025, compared to $27,886,231 provided by operating activities for the same period in 2024.
-   **Net Cash Provided by Investing Activities**: $3,239,523 for the nine months ended September 30, 2025, compared to - $5,554,039 used in investing activities for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $18,470,001 for the nine months ended September 30, 2025, compared to $11,584,038 for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to maintain and strengthen its market position and brand in the cosmetic medical treatment management market in Japan, Vietnam, and Singapore, and grow its presence globally.
-   **Non-Core Business**: The company is proceeding with the acquisition of common shares of Waqoo, Inc., a Japanese company listed on the Tokyo Stock Exchange, from the CEO of the company and other shareholders of Waqoo until the company obtains controlling interest in Waqoo.

### Related Stocks

- [SBCWW.US](https://longbridge.com/en/quote/SBCWW.US.md)

## Related News & Research

- [Nvidia Revenue Set to Increase 18X in 4 Years; Analyst Says 'Never in History' Has a Company Grown This Fast](https://longbridge.com/en/news/297126014.md)
- [Alphabet Is a 'Top 2027 Stock Pick,' Says Wolfe Research Analyst. Here's Why](https://longbridge.com/en/news/297186957.md)
- [Zhongji Innolight Fully Exercises Over-Allotment Option After Hong Kong IPO](https://longbridge.com/en/news/297095479.md)
- [Broadcom Stock (AVGO) Remains Wall Street's Pick Despite Google's Marvell Deal – Here's Why](https://longbridge.com/en/news/297093302.md)
- [Elon Musk's SPCX Now Accounts for 5% of Nvidia Revenue, Gene Munster Says: 'The Script Has Flipped'](https://longbridge.com/en/news/297157786.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**